Pharmacokinetics of engineered human monomeric and dimeric CH2 domains

mAbs

Volumn 4, Issue 4, 2012, Pages 466-474

  Gehlsen, Kurt R ^a   Gong, Rui ^b   Bramhill, Dave ^a   Wiersma, David A ^a   Kirkpatrick, Shaun A ^a   Wang, Yangping ^b,c   Feng, Yang ^b   Dimitrov, Dimiter S ^b  

^a Research Corporation Technologies Inc   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

CH2 domain; FcRn; IgG1; Protein scaffolds; Serum half life

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G1;

ARTICLE; ELIMINATION REACTION; FEMALE; HUMAN; IN VITRO STUDY; MACACA; MOUSE; NONHUMAN; PLASMA HALF LIFE; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BINDING SITES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS;

EID: 84863447184     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.20652     Document Type: Article

References (32)

1. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931.
2. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77:10557-65; PMID:12970440; http://dx.doi.org/10. 1128/JVI.77.19.10557-65.2003.
3. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008; 105:17121-6; PMID:18957538; http://dx.doi.org/10.1073/pnas.0805297105.
4. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23:1257-68; PMID:16211069; http://dx.doi.org/10.1038/nbt1127.
5. Dimitrov DS. Engineered CH2 domains (nanoantibodies). MAbs 2009; 1:26-8; PMID:20046570; http://dx.doi.org/10.4161/mabs.1.1.7480.
6. Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med 1999; 40:1536-46; PMID:10492377.
7. Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38-48; PMID:21099371; http://dx.doi.org/10.4161/mabs.3.1.14168.
8. Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011; 118:757-65; PMID:21576702; http://dx.doi.org/10.1182/blood-2010-11-317859.
9. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36; PMID:16151406; http://dx.doi.org/10.1038/nbt1142.
10. Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 305:989-1010; PMID:11162109; http://dx.doi.org/10.1006/jmbi.2000.4265.
11. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004; 17:455-62; PMID:15208403; http://dx.doi.org/10.1093/ protein/gzh053.
12. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8:2861-71; http://dx.doi.org/10.1158/1535-7163.MCT-09-0195;PMID:19825804.
13. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010; 70:1595-605; PMID:20124480; http://dx.doi.org/10.1158/0008-5472.CAN-09-2724.
14. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54:531-45; PMID:12052713; http://dx.doi.org/10.1016/S0169-409X(02)00026-1.
15. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003; 63:1288-96; PMID:12649189.
16. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. TransfusApherSci 2003; 29:255-8; PMID:14572818; http://dx.doi.org/10.1016/S1473- 0502(03)00170-8.
17. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97:4167-83; PMID:18200508; http://dx.doi.org/10.1002/jps.21278.
18. Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, To W, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 2009; 27:1186-90; PMID:19915550; http://dx.doi.org/10.1038/nbt.1588.
19. Kim JK, Tsen MF, Ghetie V, Ward ES. Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. Scand J Immunol 1994; 40:457-65; PMID:7939418; http://dx.doi.org/10.1111/j.1365-3083.1994.tb03488.x.
20. Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor. J BiolChem 2011; 286:27288-93; PMID:21669873; http://dx.doi.org/10. 1074/jbc.M111.254219.
21. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, et al. Engineered human antibody constant domains with increased stability. J BiolChem 2009; 284:14203-10; PMID:19307178; http://dx.doi.org/10.1074/jbc.M900769200.
22. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10. 1093/intimm/13.12.1551.
23. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750-5; PMID:19250681; http://dx.doi.org/10. 1016/j.molimm.2009.01.026.
24. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age.Nat Rev Immunol 2007; 7:715-25; http://dx.doi.org/10.1038/nri2155; PMID:17703228.
25. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21:2153-63; PMID:21053952; http://dx.doi.org/10.1021/ bc100261d.
26. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10. 4049/jimmunol.0903296.
27. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58; PMID:18784655; http://dx.doi.org/10.1038/clpt.2008.170.
28. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J BiolChem 2010; 285:4826-36; PMID:20018855; http://dx.doi.org/10.1074/jbc.M109.081828.
29. Kim JK, Tsen MF, Ghetie V, Ward ES. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol1994; 24:542-8; PMID:8125126; http://dx.doi.org/10. 1002/eji.1830240308.
30. Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 2010; 602:93-104; PMID:20012394; http://dx.doi.org/10.1007/978-1-60761-058-8-6.
31. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170:3528-33; PMID:12646614.
32. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110.